Table 4.
Antimicrobial resistance profiles of Enterobacteriaceae isolates from different sites of infection among patients in Northwestern Ethiopia region, 2019.
| Antimicrobials | E. coli (# T = 35) | K. pneumoniae (# T = 31) | K. ozaenae (# T = 5) | K. oxytoca (# T = 10) | E. cloacae (# T = 10) | Citrobacter spp. (# T = 5) | Proteus spp. (#T = 3) | Providencia spp. (#T = 1) | Total (# T = 100) |
|---|---|---|---|---|---|---|---|---|---|
| R % | R % | R % | R % | R % | R % | R % | R % | R % | |
| Amoxicillin | 28 (80) | 30 (96.8) | 5 (100) | 6 (60) | 10 (100) | 4 (80) | 3 (100) | 1 (100) | 87 (87) |
| Amoxicillin-clavulanic acid | 22 (62.9) | 26 (83.9) | 4 (80) | 6 (60) | 9 (90) | 4 (80) | 2 (66.7) | 1 (100) | 74 (74) |
| Nitrofurantoin | 8 (22.9) | 12 (38.7) | 2 (40) | 3 (30) | 6 (60) | 2 (40) | 1 (33.3) | 0 | 34 (34) |
| Sulphamethoxazole-trimethoprim | 21 (60) | 20 (64.5) | 4 (80) | 4 (40) | 7 (70) | 3 (60) | 2 (66.7) | 1 (100) | 62 (62) |
| Gentamicin | 10 (28.6) | 19 (61.3) | 2 (40) | 6 (60) | 6 (60) | 1 (20) | 1 (33.3) | 0 | 45 (45) |
| Chloramphenicol | 8 (22.9) | 14 (45.2) | 1 (20) | 4 (40) | 6 (60) | 4 (80) | 1 (33.3) | 0 | 38 (38) |
| Ciprofloxacin | 13 (37.1) | 17 (54.8) | 1 (20) | 3 (30) | 4 (40) | 2 (40) | 0 | 0 | 40 (40) |
| Cefotaxime | 14 (40) | 21 (67.7) | 2 (40) | 6 (60) | 9 (90) | 4 (80) | 2 (66.7) | 0 | 58 (58) |
| Ceftazidime | 14 (40) | 22 (70.1) | 4 (80) | 4 (40) | 8 (80) | 4 (80) | 1 (33.3) | 0 | 57 (57) |
| Cefoxitin, | 10 (28.6) | 16 (51.6) | 4 (80) | 4 (40) | 9 (90) | 2 (40) | 1 (33.3) | 0 | 46 (46) |
| Meropenem | 2 (5.7) | 3 (9.7) | 0 | 0 | 3 (30) | 0 | 0 | 0 | 8 (8) |
| Ertapenem | 1 (2.9) | 3 (9.7) | 0 | 0 | 2 (20) | 0 | 0 | 0 | 6 (6) |
Key: # T: number of isolates tested against each antimicrobial agent; R % percent of isolates resistance to antimicrobial agent.